Modulation of cellular and viral gene expression by the latency-associated nuclear antigen of Kaposi's sarcoma-associated herpesvirus.
Kaposi's sarcoma-associated herpesvirus (KSHV), also called human herpesvirus 8 (HHV-8), is the likely etiological agent of Kaposi's sarcoma and primary effusion lymphoma. Common to these malignancies is that tumor cells are latently infected with KSHV. Viral gene expression is limited to a few genes, one of which is the latency-associated nuclear antigen (LANA), the product of ORF73. Examination of the primary sequence of LANA reveals some structural features reminiscent of transcription factors, leading us to hypothesize that LANA may regulate viral and cellular transcription during latency. In reporter gene-based transient transfection assays, we found that LANA can have either positive or negative effects on gene expression. While expression of a reporter gene from several synthetic promoters was increased in the presence of LANA, expression from the human immunodeficiency virus (HIV) long terminal repeat (LTR)-and from NF-kappaB-dependent reporter genes-was reduced by LANA expression. In addition, the promoter of KSHV ORF73 itself is activated up to 5.5-fold by LANA. This autoregulation may be important in tumorigenesis, because two other genes (v-cyclin and v-FLIP) with likely roles in cell growth and survival are also controlled by this element. To identify cellular genes influenced by LANA, we employed cDNA array-based expression profiling. Six known genes (and nine expressed sequence tags) were found to be upregulated in LANA-expressing cell lines. One of these, Staf-50, is known to inhibit expression from the HIV LTR; most of the other known genes are interferon inducible, although the interferon genes themselves were not induced by LANA. These data demonstrate that LANA expression has effects on cellular and viral gene expression. We suggest that, whether direct or indirect in origin, these effects may play important roles in the pathobiology of KSHV infection.
Renne
R
R
Division of Hematology/Oncology, Case Western Reserve University, Cleveland, Ohio 44106, USA. rfr3@po.cwru.edu
Barry
C
C
Dittmer
D
D
Compitello
N
N
Brown
P O
PO
Ganem
D
D
D000818:Animals; D000956:Antigens, Viral / Q000502:physiology*; D015152:Blotting, Northern; D019556:COS Cells; D004268:DNA-Binding Proteins / Q000235:genetics; D005786:Gene Expression Regulation; D019288:Herpesvirus 8, Human / Q000502:physiology*; D006801:Humans; D015778:Minor Histocompatibility Antigens; D009687:Nuclear Proteins / Q000502:physiology*; D011401:Promoter Regions, Genetic; D012333:RNA, Messenger / Q000032:analysis; D012097:Repressor Proteins / Q000235:genetics; D050794:STAT1 Transcription Factor; D020079:Terminal Repeat Sequences; D015534:Trans-Activators / Q000235:genetics; D014157:Transcription Factors / Q000235:genetics; D000070584:Tripartite Motif Proteins
D000956:Antigens, Viral; D004268:DNA-Binding Proteins; D015778:Minor Histocompatibility Antigens; D009687:Nuclear Proteins; D012333:RNA, Messenger; D012097:Repressor Proteins; D050794:STAT1 Transcription Factor; C494079:STAT1 protein, human; C094314:TRIM22 protein, human; D015534:Trans-Activators; D014157:Transcription Factors; D000070584:Tripartite Motif Proteins; C109540:latency-associated nuclear antigen